NCT00000193
Withdrawn
Phase 2
Neurobiology of Opioid Dependence: 2
ConditionsOpioid-Related Disorders
DrugsGamma hydroxybutyric
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Opioid-Related Disorders
- Sponsor
- Yale University
- Locations
- 1
- Primary Endpoint
- Behavioral, subjective, measures of naloxone-preci
- Status
- Withdrawn
- Last Updated
- 10 years ago
Overview
Brief Summary
The purpose of this study is to evaluate the effects of gamma hydroxybutyric on naloxone-precipitated opiate withdrawal.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Behavioral, subjective, measures of naloxone-preci
Phsyiological, neuroendocrine measures of naloxone
Study Sites (1)
Loading locations...
Similar Trials
Withdrawn
Phase 2
Neurobiology of Opioid Dependence: 1 - 1Opioid-Related DisordersNCT00000192Yale University
Withdrawn
Phase 2
Neurobiology of Opioid Dependence: 3 - 3Opioid-Related DisordersNCT00000194Yale University
Withdrawn
Phase 2
Neurobiology of Opioid Dependence: 5 - 5Opioid-Related DisordersNCT00000196Yale University
Withdrawn
Phase 2
Neurobiology of Opioid Dependence: 4 - 4Opioid-Related DisordersNCT00000195Yale University
Completed
Phase 1
Physiological, Behavioral and Subjective Effects of Drugs (GHB)Sedative AbuseNCT00058955Orphan Medical20